BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform Jun 26, 2025 04:34PM
BMO Capital sees 70% chance Verve Therapeutics (VERV) receives CVR payout Jun 17, 2025 11:22AM
BMO Capital Reiterates Outperform Rating on Verve Therapeutics (VERV), PT $30 Apr 15, 2025 08:51AM
BMO Capital Sees Upside Potential for Verve Therapeutics (VERV) Mar 25, 2025 09:10AM
Verve Therapeutics (VERV) PT Lowered to $30 at BMO Capital Apr 3, 2024 07:43AM


Dec 1, 2023 04:00PM Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Nov 28, 2023 10:37PM Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Nov 28, 2023 04:03PM Verve Therapeutics (VERV) Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Nov 28, 2023 04:01PM Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Jun 16, 2022 04:16PM UPDATE: BMO Capital Starts Verve Therapeutics (VERV) at Outperform, Top Pick